Share Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Copy link

November 25, 2025

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

21 minutes

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.

...more